1. E. K. Rowinsky, M. Wright, B. Monsarrat, G. J. Lesser, and R. C. Donehower. Taxol: pharmacology, metabolism and clinical implications. Cancer Surv. 17:283–301 (1993).
2. W. P. Mcguire, W. J. Hoskins, M. F. Brady, P. R. Kucera, E. E. Partridge, K. Y. Look, and C. D. L. Pearson. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1–6 (1996).
3. J. P. Neijt, S. A. Engelholm, P. O. Witteveen, M. K. Tuxen, P. G. Sorensen, M. F. Hasen, F. Hirsch, C. Sessa, C. Swart, H. C. V. Houwelingen, B. Lund, and S. W. Hamsen. Paclitaxel (175 mg/m2 over 3hours) with cisplatin or carboplatin in previously untreated ivarian cancer: an interim analysis. Semin. Oncol. 24:36–39 (1997).
4. L. A. Martello, P. Verdier-Pinard, H. J. Shen, L. He, K. Torres, G. A. Orr, and S. B. Horwitz. Elevated level of microtuble destabilizing factors in a Taxol-resistant/dependent A549 cell line with an α-tublin mutation. Cancer Res. 63:1207–1213 (2003).
5. S. Mozzetti, C. Ferlini, P. Concolino, F. Pilippetti, G. Raspaglio, S. Prislei, D. Gallo, E. Martinelli, F. O. Ranelletti, G. Ferrandina, and G. Scambia. Class III β-tublin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 11:298–305 (2005).